Amedisys (AMED) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program
August 4, 2021 4:05 PM EDTBATON ROUGE, La., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2021.
Three-Month Periods Ended June 30, 2021 and 2020
Net service revenue increased $79.2Â million to $564.2Â million compared to $485.0Â million in 2020.Net income attributable to Amedisys, Inc. of $80.1Â million compared to $34.7Â million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $2.43 compared to $1.04 in 2020.Adjusted Quarterly Results*
Adjusted EBITDA of $83.8Â million compared to $66.4Â million in 2020.Adjusted net service revenue of $557.6Â million compared to $485.0Â million in... More


